Clinical trials: Neoplasms, Oral
Kidney Cancers
Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
The goal of this prospective, single-arm feasibility study is to evaluate the safety and feasibility of using Gleolan® (5-aminolevulinic acid), an FDA-approved drug currently used during brain tumor surgery, in adults with…
- Trial name
- NCT07828704
- Testing
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Henry Ford Health System
Head and Neck Neoplasms
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- NCT00094081
- Testing
- tirapazamine (SR259075), cisplatin, Radiation Therapy
- Where
- 10 sites in United States
- Volunteers
- 861 people
- Sponsor
- Sanofi
Adults, Hematological Malignancy
A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
Patients with haematologic malignancies are increasingly treated by Oral Anticancer Medications (OAMs), increasing the challenge of ensuring optimal adherence to treatment.
- Conditions
- Adults, Hematological Malignancy, Oral Antineoplastic Agents
- Trial name
- MADESIO (NCT04613765)
- Testing
- Measure adherence behaviors
- Where
- 2 sites in Belgium
- Volunteers
- 113 people
- Sponsor
- Jules Bordet Institute
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT07012044
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 15 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, AML
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
- Trial name
- OPAL (NCT00780598)
- Testing
- Tosedostat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- Chroma Therapeutics
Castration-Resistant Prostate Cancer
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Trial name
- AFFIRM (NCT00974311)
- Testing
- Enzalutamide
- Where
- 249 sites in United States, Argentina and 13 more
- Volunteers
- 1,199 people
- Sponsor
- Pfizer
Breast Cancer
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
- Trial name
- NCT00721409
- Testing
- PD 0332991, letrozole
- Where
- 104 sites in United States, Canada and 10 more
- Volunteers
- 177 people
- Sponsor
- Pfizer
Oral Squamous Cell Carcinoma (OSCC)
Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma
This is a Phase II, single-centre, non-randomized, single-arm clinical trial to investigate the efficacy and safety of neoadjuvant nivolumab therapy in adult participants with resectable, locoregionally advanced Oral Squamous…
- Trial name
- NOCANO (NCT07514767)
- Testing
- Nivolumab (240 mg)
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Prof. Lars Olaf Cardell
CML, Chronic Myelogenous Leukemia
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase…
- Conditions
- CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
- Trial name
- NCT03578367
- Testing
- Asciminib add-on, Imatinib, Nilotinib
- Where
- 30 sites in United States, Austria and 13 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728.
- Trial name
- NCT03410927
- Testing
- TAS0728
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Taiho Oncology, Inc.
Colo-rectal Cancer
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
Introduction: In the 2023-2025 period, colorectal cancer (CRC) will be the third most common type of cancer in Brazil. The most commonly used therapeutic approaches are chemotherapy (QTx) and radiotherapy (RTx).
- Trial name
- NCT06576986
- Testing
- Symbiotic, Maltodextrin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of Minas Gerais
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
This phase I trial will determine the Maximum Tolerated Dose (MTD) of BKM120 when given together with fulvestrant in treating postmenopausal patients with estrogen receptor-positive (ER+) stage IV breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01339442
- Testing
- BKM120, Fulvestrant, biopsy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Chemo-radiation Induced Nausea and Vomiting
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT)…
- Trial name
- NCT02991456
- Testing
- Rolapitant, Ondansetron
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Head and Neck Tumors
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
Currently, patients with cancer of oral cavity or oropharynx T1-T2N0 classified, are treated surgically with systematic lymph node dissection while in 70%, there is no lymph node metastasis.
- Trial name
- SentiMERORL (NCT02855723)
- Testing
- Surgery: GS strategy, Surgery: Classic strategy
- Where
- France
- Volunteers
- 307 people
- Sponsor
- University Hospital, Montpellier
Oral Squamous Cell Carcinoma (OSCC)
A Prospective Single-Arm Study（NCLDR）
To investigate the safety and efficacy of low-dose radiotherapy combined with chemotherapy and immunotherapy as neoadjuvant therapy for locally advanced oral squamous cell carcinoma (OSCC), and to explore whether low-dose…
- Trial name
- NCLDR (NCT07028918)
- Testing
- Low dose radiotherapy regimen, New adjuvant immunotherapy regimen, Surgical treatment
- Volunteers
- 35 people
- Sponsor
- Qilu Hospital of Shandong University
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Oral Mucositis in Head and Neck Cancer, Chemo-radiotherapy
A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.
Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM).
- Trial name
- NCT07293013
- Testing
- olive oil mouthwash
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chiayi Christian Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.